

Covid candidate vaccines

As of 31st August 2020

Source: RAPS

Candidate	Sponsor	Trial status	Institution	Funding
AAVCOVID	Massachusetts Eye and Ear; Massachusetts General Hospital; University of Pennsylvania	Pre-clinical		Wyc Grousbeck; Emilia Fazzalari
Ad26.COVS-2	Johnson & Johnson	Phase 1/2	Johnson & Johnson	Operation Warp Speed; Johnson & Johnson; BARDA
Ad5-nCoV	CanSino Biologics	Phase 3	Tongji Hospital; Wuhan, China	CanSino Biologics
AdCOVID	Altimune	Pre-clinical	University of Alabama at Birmingham	Altimune
Adenovirus-based vaccine	ImmunityBio; NantKwest	Pre-clinical		Operation Warp Speed
AdimrSC-2f	Adimmune	Phase 1	Adimmune	
Adjuvant recombinant vaccine candidate	Anhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of the Chinese Academy of Sciences	Phase 2		

AZD1222/Covishield	The University of Oxford; AstraZeneca; IQVIA; Serum Institute of India	Phase 2/3	The University of Oxford, the Jenner Institute	Operation Warp Speed; UK Ministry of Health; The University of Oxford; BARDA
Bacillus Calmette-Guerin (BCG) live-attenuated vaccine	University of Melbourne and Murdoch Children's Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital	Phase 2/3	University of Melbourne and Murdoch Children's Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital	Murdoch Children's Research Institute; UMC Utrecht
bacTRL-Spike	Symvivo	Pre-clinical	Symvivo Corporation	Symvivo Corporation
BBIBP-CorV	Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	Phase 1/2	Henan Provincial Center for Disease Control and Prevention	Ministry of Science and Technology, China
BNT162	Pfizer, BioNTech	Phase 2/3	Multiple study sites in Europe and North America	Pfizer; BioNTech
ChAd-SARS-CoV-2-S	Washington University School of Medicine in St. Louis	Pre-clinical	Washington University School of Medicine in St. Louis	
CoronaVac	Sinovac	Phase 3	Sinovac Research and Development Co., Ltd.	Sinovac Research and Development Co., Ltd.
COVAX-19	Vaxine Pty Ltd.	Phase 1	Royal Adelaide Hospital	NIAID

Covaxin	Bharat Biotech; National Institute of Virology	Phase 2		
gp96-based vaccine	Heat Biologics	Pre-clinical	University of Miami Miller School of Medicine	
GRAd-COV2	Genexine	Phase 1/2		GenexineGenexine
GRAd-COV2	ReiThera; Leukocare; Univercells	Phase 1	Lazzaro Spallanzani National Institute for Infectious Diseases	
HaloVax	Voltron Therapeutics, Inc.; Hoth Therapeutics, Inc.	Pre-clinical	MGH Vaccine and Immunotherapy Center	
HDT-301	University of Washington; National Institutes of Health Rocky Mountain Laboratories; HDT Bio Corp	Pre-clinical		University of Washington; National Institutes of Health Rocky Mountain Laboratories; HDT Bio Corp
Ii-Key peptide COVID-19 vaccine	Generex Biotechnology	Pre-clinical	Generex	Generex
Inactivated vaccine	Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	Phase 3	Henan Provincial Center for Disease Control and Prevention	Ministry of Science and Technology, China
INO-4800	Inovio Pharmaceuticals	Phase 1/2	Center for Pharmaceutical Research, Kansas City, Mo.; University of Pennsylvania, Philadelphia	Inovio Pharmaceuticals
LineaDNA	Takis Biotech	Pre-clinical	Takis Biotech	Takis Biotech

LUNAR-COV19	Arcturus Therapeutics and Duke-NUS Medical School	Phase 1/2	Duke-NUS Medical School, Singapore	Arcturus
Molecular clamp vaccine	CSL; The University of Queensland	Phase 1		CEPI; CSL
mRNA lipid nanoparticle (mRNA-LNP) vaccine	CanSino Biologics, Precision NanoSystems	Early research		
mRNA-1273	Moderna	Phase 3	Kaiser Permanente Washington Health Research Institute	Operation Warp Speed; NIAID, BARDA (\$483 million)
mRNA-based vaccine	CureVac	Phase 1	CureVac	CureVac; German federal government
mRNA-based vaccine	Chulalongkorn University's Center of Excellence in Vaccine Research and Development	Pre-clinical		
NVX-CoV2373	Novavax	Phase 2b	Novavax	Novavax, CEPI, Department of Defense (\$60 million)
PittCoVacc	UPMC/University of Pittsburgh School of Medicine	Pre-clinical	University of Pittsburgh	CEPI
Plant-based adjuvant COVID-19 vaccine candidate	Medicago; GSK; Dynavax	Phase 1	Medicago	Medicago
Protein subunit vaccine	University of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine Centre	Pre-clinical	University of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine Centre	no information

Recombinant vaccine	Vaxart	Pre-clinical	Vaxart	no information
Recombinant vaccine	Sanofi, Translate Bio	Pre-clinical		BARDA
SCB-2019	GlaxoSmithKline, Sanofi, Clover Biopharmaceuticals, Dynavax and Xiamen Innovax	Phase 1	Linear Clinical Research (Australia)	CEPI
Self-amplifying RNA vaccine	Imperial College London	Phase 1/2	Imperial College London	UK Secretary of State for Health; UK Secretary of State for Business, Energy and Industrial Strategy
Sputnik V	Gamaleya Research Institute, Acellena Contract Drug Research and Development	Phase 1/2	Various	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
T-COVIDTM	Altimune	Pre-clinical		Altimune
V590	Merck; IAVI	Phase 1		BARDA
V591	University of Pittsburgh's Center for Vaccine Research	Pre-clinical	University of Pittsburgh ; Themis Biosciences; Institut Pasteur	Merck
ZyCoV-D	Zydus Cadila	Phase 2	Zydus Cadila	